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Background: MicroRNAs (miRNAs) regulate gene expression by binding to mRNA, and can function as oncogenes
or tumor suppressors depending on the target. In this study, using qRT-PCR, we examined the expression of six
miRNAs (miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145) in tumors from 193 prospectively recruited
patients with colorectal cancer, and associations with clinicopathological parameters and patient outcome were
analyzed. The miRNAs were chosen based on previous studies for their biomarker potential and suggested
biological relevance in colorectal cancer.
Methods: The miRNA expression was examined by qRT-PCR. Associations between miRNA expression and
clinicopathological variables were explored using Mann–Whitney U and Kruskal-Wallis test while survival was
estimated using the Kaplan-Meier method and compared using the log-rank test.
Results: MiR-101 was hardly expressed in the tumor samples, while for the other miRNAs, variable expression levels
and expression ranges were observed, with miR-21 being most abundantly expressed relative to the reference
(RNU44). In our study cohort, major clinical significance was demonstrated only for miR-31, as high expression was
associated with advanced tumor stage and poor differentiation. No significant associations were found between
expression of the investigated miRNAs and metastasis-free or overall survival.
Conclusions: Investigating the expression of six miRNAs previously identified as candidate biomarkers in colorectal
cancer, few clinically relevant associations were detected in our patient cohort. Our results emphasize the
importance of validating potential tumor markers in independent patient cohorts, and indicate that the role of
miRNAs as colorectal cancer biomarkers is still undetermined.
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MicroRNAs (miRNAs) are a class of small, non-coding
RNAs (19–22 nucleotides) that function as posttranscrip-
tional gene regulators by binding to the 3’UTR of mRNA,
and one miRNA may potentially down-regulate multiple
mRNA targets. More than 1500 human miRNAs are cur-
rently annotated in the miRBase [1], and it has been pre-
dicted that as many as 30% of protein-encoding genes
may be regulated by miRNAs [2]. The discovery that
miRNAs may function as oncogenes or tumor suppressors* Correspondence: kristina.schee@rr-research.no
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reproduction in any medium, provided the ordepending on the target mRNA, has instigated intensive
research to determine the role of these molecules in can-
cer. MiRNAs are chemically very stable, and can be
detected by a range of high-throughput detection methods
in tissue, serum and plasma as well as in urine and feces,
and are for these reasons considered to have great poten-
tial as cancer biomarkers.
In colorectal cancer (CRC), treatment decisions are
still based essentially on anatomical extent of disease at
diagnosis, and the search for better biomarkers is war-
ranted. Several miRNAs with potential biological and
clinical relevance have been identified and are being
explored as diagnostic, prognostic and predictive bio-
markers [3-6]. Based on previous studies and our recenttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2407/12/505review of this topic, six candidate miRNAs, miR-21,
miR-31, miR-92a, miR-101, miR-106a and miR-145
(Table 1), were chosen for analysis in a cohort of 193
prospectively recruited patients receiving curative sur-
gery for CRC [7-13]. Expression of the miRNA was
determined by qRT-PCR and associations with clinico-
pathological parameters and outcome were analyzed.
Methods
Patient cohort
316 patients, recruited from five hospitals in the Oslo re-
gion between the year 1998 and 2000 [15], were pro-
spectively included in the study at the time of primary
surgery for assumed or verified colorectal cancer. The
study was approved by the Regional Ethics Committee
(Health Region II, Norway) and informed consent was
obtained from the patients. At surgery, resected speci-
mens were routinely processed for histopathological as-
sessment and additional tumor tissue was sampled and
snap-frozen in liquid nitrogen. A number of cases were
excluded from statistical analysis for the following rea-
sons: not invasive cancer (25), histology other than
adenocarcinoma (5), distant metastasis at the time of
surgery (34, tissue samples not available), preoperative
chemoradiotherapy (2), inadequate surgical margins (7),
unknown stage of disease (1), freshly frozen tissue sam-
ples not obtainable (46), and high Ct-values (>37; n=3).
The study population thus consisted of 193 patients in
TNM stage I-III (Table 2). Follow-up data was obtained
from the participating hospitals and from the general
practitioners (for the patients not attending scheduled
controls). Metastasis was verified by radiological examin-
ation and survival data was obtained from the National
Registry of Norway and updated by October 1st 2008
with the cause of death registered and classified as death
from colorectal cancer, death of other cause or death of
unknown cause.Table 1 Mature sequence, miRBase accession number and pro







hsa-miR-21 UAGCUUAUCAGACUGAUGUUGA MIMAT0000076 Overall
hsa-miR-31 AGGCAAGAUGCUGGCAUAGCU MIMAT0000089 Tumor
hsa-miR-92a UAUUGCACUUGUCCCGGCCUGU MIMAT0000092 Plasma
hsa-miR-101 UACAGUACUGUGAUAACUGAA MIMAT0000099 Increas
hsa-miR-106a AAAAGUGCUUACAGUGCAGGUAG MIMAT0000103 Disease
overall
hsa-miR-145 GUCCAGUUUUCCCAGGAAUCCCU MIMAT0000437 TumorMiRNA selection
MiRNA selection was based on previous studies and our
literature review [11], identifying miRNA with proposed
clinical relevance in CRC, including published articles
leading up to the year 2009. We wished to examine
selected miRNAs in our CRC cohort and their relevance
with clinicopathological data and outcome parameters
(Table 2). The following six miRNAs were chosen for
analysis; miR-21, miR-31, miR-92a, miR-101, miR-106a
and miR-145 [7-13].
Sample preparation and RNA isolation
Biopsies were sampled and snap frozen in liquid nitrogen
and stored at −80°C. The biopsies were sectioned using a
cryostat microtome and hematoxylin-eosin stained slides
were evaluated for tumor content by a pathologist (median
tumor content in the samples was 50%, range 30 - 80%).
The tumor tissue was sliced into 10 μm sections using a
cryostat microtome, aliquoted into 1.5 ml Micro tubes
(Sarstedt, Nümbrecht, Germany) and stored at −80°C.
RNA was isolated from the tumor tissue using TriReagent
(Ambion Inc, TX) according to the manufacturer’s proto-
col and the total RNA concentration was measured by
Nanodrop (ND-1000).
qRT-PCR
Total RNA from 196 patients was used to reversely tran-
scribe miRNAs using TaqMan MicroRNA assays (Ap-
plied Biosystems, Foster City, CA). Each reverse
transcriptase reaction contained 10 ng of total RNA
(5μl), 0.15 μl dNTP (100 mM total), 1.0 μl Multiscribe
RT enzyme (50 U/μl), 1.5 μl 10X RT buffer, 0.19 μl
RNase Inhibitor (20 U/μl) , 4.16 μl nuclease free water
(Sigma-Aldrich, Ayshire, UK) and 3.0 μl 5X RT Primer.
The 15 μl reaction volumes were incubated in 8-well PCR
strip tubes (Sarstedt) in a GeneAmp PCR System 9700




survival High expression associated
with poor OS
[14]
stage/ differentiation High expression associated
with advanced tumor stage
and poorly differentiated tumors
[10]
marker Elevated levels as a possible
diagnostic marker
[13]






poor disease free and overall survival.
[7]
size Low expression associated with
large tumor size
[9]
Table 2 Median expression levels of the six selected miRNAs and associations with clinicopathological data
Number (percent) miR-21 miR-31 miR-92a miR-101 miR-106a miR-145
Gender
Female 81 (42) 7.78 0.07 1.64 0.02 1.16 0.43
Male 112 (58) 7.53 0.03 2.12 0.02 0.93 0.48
p-value 0.45 0.14 0.52 0.78 0.43 0.99
TNM
I 35 (18) 5.22 0.02 2.41 0.02 1.24 0.34
II 97 (50) 7.67 0.06 2.09 0.02 1.10 0.48
III 61 (32) 7.78 0.07 1.59 0.02 0.85 0.51
p-value 0.23 0.02 0.80 0.86 0.54 0.30
pT
1 4 (2) 7.90 0.02 2.51 0.02 1.16 0.36
2 36 (19) 5.15 0.02 2.45 0.02 1.26 0.36
3 133 (69) 7.67 0.05 1.74 0.02 0.88 0.46
4 20 (10) 8.50 0.14 2.58 0.02 1.33 0.58
p-value 0.37 0.004 0.61 0.76 0.52 0.70
pN
0 132 (68) 7.53 0.04 2.12 0.02 1.15 0.44
1 39 (20) 7.67 0.05 1.73 0.02 0.89 0.46
2 22 (11) 8.47 0.09 1.39 0.02 0.82 0.59
p-value 0.82 0.31 0.60 0.95 0.54 0.63
Differentiation
Well 6 (3) 3.58 0.02 1.09 0.01 0.38 0.24
Intermediate 167 (87) 7.67 0.04 2.14 0.02 1.16 0.45
Poor 20 (10) 6.83 0.20 0.95 0.02 0.70 0.69
p-value 0.28 0.001 0.003 0.33 0.01 0.12
Tumor localization
Colon 129 (67) 7.52 0.07 1.62 0.02 0.87 0.43
Rectum 64 (33) 7.77 0.02 2.58 0.02 1.27 0.67
p-value 0.50 0.02 0.05 0.32 0.05 0.08
Lymphocyte infiltration
High 26 (14) 7.93 0.09 1.96 0.02 0.88 0.63
Intermediate 125 (65) 7.78 0.03 2.14 0.02 1.01 0.51
Low 40 (21) 6.91 0.08 1.46 0.02 1.04 0.33
p-value 0.47 0.19 0.49 0.82 0.37 0.14
Vascular invasion
Present 38 (20) 7.73 0.07 1.54 0.02 1.17 0.59
Absent 155 (80) 7.36 0.04 2.01 0.02 0.98 0.43
p-value 0.30 0.23 0.43 0.27 0.94 0.05
Perineural invasion
Present 16 (8) 8.60 0.16 1.68 0.02 1.05 0.35
Absent 177 (92) 7.54 0.04 1.95 0.02 0.98 0.48
p-value 0.42 0.43 0.60 0.29 0.83 0.49
Perinodal growth*
Present 38 (62) 8.09 0.11 1.46 0.02 0.81 0.52
Absent 23 (38) 7.36 0.03 2.01 0.02 1.10 0.36
p-value 0.77 0.36 0.30 1.00 0.18 0.49
*Associations between miRNA expression and clinicopathological variables were explored using Mann–Whitney or Kruskal-Wallis test as appropriate; p-values are
given in italic. Total number of patients included in the analyses was 193, median age was 73 years.
** Perinodal growth was only assessed in the lymph node positive patients.















Figure 1 MiRNA expression in tumor samples. Boxplot showing
the relative expression distribution of miR-21, miR-31, miR-92a, miR-101,
miR-106a and miR-145. qRT-PCR was performed and Ct values for each
miRNA was normalized against RNU44 and the relative expression was
calculated using 2-dCt method. Circles represent outliers while stars
represent extreme outliers.
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performed using Applied Biosystems 7500 real-time
PCR system. The reversely transcribed miRNAs were
diluted 1:20 before adding 1.3 μl to 10 μl 2X Universal
PCR Master Mix (no AmpErase UNG), 7.7 μl water and
1.0 μl 20X MicroRNA Assay. A total volume of 20 μl
per reactions was incubated in 96-well MicroAmp
plates (Applied Biosystems) for 10 min 95°C followed by
40 cycles of 15 sec. 95°C and 60 sec. 60°C. All samples
were run in duplicates.
RNU6B and RNU44 were tested as potential reference
genes and performed equally well, and RNU44 was
selected for further analysis [16]. Each miRNA was nor-
malized against RNU44 and the relative expression was
calculated using 2-dCt method [17].
Statistical analysis
All statistical analyses were performed using SPSS ver-
sion 18.0 (SPSS Inc., Chicago, MO) and P-values < 0.05
were considered to be statistically significant. Associa-
tions between miRNA expression and clinicopathologi-
cal variables were explored using Mann–Whitney U and
Kruskal-Wallis test as appropriate. Survival was esti-
mated using the Kaplan-Meier method and compared
using the log-rank test. Overall and metastasis-free sur-
vival was calculated from date of surgery until date of
death or diagnosis of metastasis.
Results
MiRNA expression in tumor samples
The most abundantly expressed miRNA relative to the
reference was miR-21, and it also exhibited the widest
expression range among the examined candidates (me-
dian relative expression ratio was 7.7; range 0.4-61.0). In
contrast, miR-101 was hardly detectable in any of the
samples (0.02; 0–0.13), and miR-31 exhibited low ex-
pression but a wider expression range (0.04; 0–2.6). The
remaining three miRNAs, miR-92a (1.9; 0.04-24.4),
miR-106a (1.0; 0.1-18.1), and miR-145 (0.5; 0.04-29.8)
exhibited intermediate expression levels and variability
between samples (Figure 1).
MiRNA expression and associations with
clinicopathological parameters
To explore the clinical significance of these findings, asso-
ciations with clinicopathological variables were investi-
gated. Somewhat surprisingly, few significant associations
were detected between expression of miR-21, miR-92a,
miR-101, miR-106a and miR-145 and clinicopathological
variables, including age, gender, tumor stage, differenti-
ation, localization and specific histomorphologic charac-
teristics such as vascular invasion, perineural infiltration
and lymphocyte infiltration (Table 2). MiR-92a and
miR-106a were associated with differentiation, as highermedian expression levels were found in intermediately
differentiated tumors than in well and poorly differen-
tiated tumors (p=0.003 and p=0.01, respectively). Also,
some associations were found between miR-31, miR-92a
and miR106a expression and tumor localization, as
miR-31 exhibited higher expression in colon tumors
while miR-92a and miR106a had higher expression
levels in rectal tumors (p=0.02, p=0.05 and p=0.05,
respectively).
For miR-31, an association with tumor stage, and in
particular with pT stage was found, as relative median
expression of miR-31 increased with pT stage (0.015,
0.02, 0.05, and 0.14 for pT1, pT2, pT3, and pT4, respect-
ively; p=0.004, Kruskal-Wallis test) (Figure 2 and
Table 2). High miR-31 expression was also associated
with poorly differentiated tumors, as relative mean ex-
pression was 0.2, 0.04 and 0.02 for poor, intermediate
and well differentiated tumors, respectively (p=0.001,
Kruskal-Wallis test), which is also in accordance with
previous findings [12].
MiRNA expression and associations with patient outcome
To analyze associations with outcome, survival was esti-
mated using the Kaplan-Meier method and compared
using the log-rank test. As there are no generally recog-
nized cut-off values for the miRNAs analyzed in this
work, different values were explored to arrange data (in-
cluding mean, median and tertiles). Regardless of the
cut-off value used, we found no significant associations
between expression of any of the analyzed miRNAs and
metastasis-free (Figure 3) or overall survival. Similar
results were obtained using univariate Cox regression
Figure 2 MiR-31 expression according to pT-stage at diagnosis. Boxplot showing qRT-PCR relative quantities (using the 2-dCt method) of
miR-31 according to pT-stage, indicating that expression of miR-31 increased with increasing pT stage (p=0.004, Kruskal-Wallis test). Circles
represent outliers while stars represent extreme outliers.
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variables (data not shown).
Discussion
Although miR-31 was expressed at relatively low levels
compared with some of the other candidates, high ex-
pression was associated with advanced tumor stage at
diagnosis, and particularly with pT-stage, in accordance
with previous results [9,10]. There are multiple predicted
targets for miR-31, but few have been fully validated at
present. One proposed target of miR-31 that has been
experimentally investigated is Special AT-rich Binding
protein 2 (SATB2), which is involved in transcriptional
regulation and chromatin remodeling [18]. In an immu-
nohistochemical study performed in 146 colorectal
tumors, low expression of SATB2 was associated with
metastasis development and poor prognosis [19]. An-
other target that has been shown to be regulated by
miR-31 is the T lymphoma Invasion And Metastasis
gene 1 (TIAM1), which is a guanidine exchange factor
for Rac GTPase and when over-expressed, it prevents
TGF-β and TNF-α dependent motility and invasion in
CRC cell lines [20]. The postulated effects of miR-31 on
SATB2 and TIAM1 are consistent with the associations
between miR-31 expression and advanced tumor stage,
observed by us and others, but clearly, the regulatory ac-
tivity of miR-31 is still incompletely understood in CRC.
MiR-92a was included in the analyses because it has
been proposed as an early-detection biomarker in
plasma and stool [13,21]. In general, one would expect
an early-detection biomarker to be ubiquitously
expressed in the tissue of interest, and although severaltumors in our study had relatively high levels of miR-92a,
low levels were found in a substantial proportion of the
samples. Also, over-expression of miR-92a has been found
in other cancer types, such as hepatocellular carcinoma
and leukemia [22,23], which suggest that further evalu-
ation is necessary to determine its specificity and sensitiv-
ity as an early-detection biomarker. Although miR-92a
was not primarily included in this study for its prognostic
relevance, it was recently proposed as a key oncogenic
component of the miR-17-92 cluster through targeting
and down-regulating the proapoptotic protein Bim in
CRC, suggesting that the functional role of miR-92a in
CRC should be further elucidated [24].
MiR-21 is one of the more extensively studied miRNAs
in CRC and was included in our study because of its pro-
posed association with advanced tumor stage and outcome
in CRC [12,14]. In the present work, miR-21 exhibited the
highest relative expression and the widest expression range
of the examined candidates, but no significant associations
with clinicopathological data or outcome were found. Al-
though some investigators have identified this miRNA as
clinically relevant, other exploratory studies of miRNA ex-
pression in CRC have not been able to verify these findings
[25-27]. It has been speculated that discrepancies might be
explained by the composition of patient cohorts, particu-
larly regarding tumor localization, as the association be-
tween miR-21 and survival has primarily been documented
in colon cancer [28]. However, in our cohort no differences
were found when comparing the clinical relevance of
miR-21 expression in colon and rectum cancer. In most of
the previous studies, miR-21 expression was reported rela-
tive to paired normal tissues, whereas only tumor tissue
Figure 3 MiRNA expression and metastasis-free survival. Kaplan-Meier survival plots of metastasis-free survival for the six selected miRNAs.
The 193 patients were divided into low and high expression of the respective miRNA based on the median value (low expression n=97 and high
expression n=96).
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terpretation of results [17]. However, among the reports
that did not identify miR-21 as relevant for outcome in
CRC, both analysis of tumor tissue alone and paired
tumor and normal samples were used, suggesting that this
may not be the only explanation for the discrepancies.When the primary objective is to identify cancer spe-
cific molecules, the inclusion of normal tissues is neces-
sary, whereas, in the current project the aim was to
evaluate previously identified potential biomarkers,
which is a different setting. Importantly, normal tissue is
often not obtainable for analysis, and expression of
Schee et al. BMC Cancer 2012, 12:505 Page 7 of 8
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ably between patients, and not necessarily in concert with
the corresponding tumor sample. Thus, it is probably both
practicable and necessary to develop assays that are inde-
pendent of normal tissue. Another related challenge con-
cerns the definition of biologically relevant cut-off levels,
which have not been determined for specific miRNA in
different tissues. We explored multiple cut-off levels, but
associations with clinicopathological parameters and out-
come for all the candidates remained relatively similar.
MiR-101, miR-145 and miR-106a have previously been
associated with cancer-relevant biological processes,
such as growth, proliferation and inhibition of apoptosis,
or with clinical outcome in CRC [7-9], but few associa-
tions with clinicopathological parameters or outcome
were found in our cohort. MiR-101 was hardly detect-
able in tumor samples, which is in accordance with its
proposed function as a tumor suppressor that is lost
during tumorigenesis. Interesting recent findings in pan-
creatic cancer suggest miR-101 as a key regulator of
stem cell protein markers; its loss favoring the stem cell
phenotype and its re-expression constituting a possible
therapeutic strategy [29]. Down-regulation of miR-145
was also identified as an early event in CRC carcinogen-
esis, which might explain why associations with clinical
variables in invasive tumors were absent in our tumor
panel. The biological relevance of miR-145 in CRC has,
however, been repeatedly confirmed, and this miRNA is
also being explored as a therapeutic target [30,31].
MiR-106a was in a recent review identified as consistently
up-regulated in CRC (relative to normal colon) which
would be in agreement with our findings [32]. It has also
been identified in stool samples in CRC patients, and has
been suggested as an early detection biomarker [33], but
even if extensively studied in several cancer forms, its
function and clinical relevance remain unclear.
Conclusions
It has become evident over the last decade that miRNAs
contribute to the pathogenesis of a broad variety of human
disease, including cancer. Their relatively small number
combined with large potential downstream regulatory
effects and unique chemical stability make these molecules
interesting biomarker candidates. Although the miRNAs
analyzed in the present study were chosen on the basis of
biomarker potential and biological relevance in CRC, major
clinical significance could only be confirmed for miR-31 in
our study cohort. It seems clear that the role of miRNAs as
colorectal cancer biomarkers is still undetermined, empha-
sizing the need for further investigations in the exploratory
setting and to validate potential biomarkers.
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